Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) reported Q2 2017 earnings this Morning, coming in at $0.30 per share, missing Wall Street’s estimates of $0.51 per Share. Revenue for the quarter came in at $50.10 million missing the streets estimates of $52.52 million
Analyst Coverage For Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
These are 1 Sell Rating, 3 Buy Ratings .
The current consensus rating for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is Buy (Score: 2.50) with a consensus target price of $84.00 , a potential (79.60% upside)Recent Insider Trading for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)
- On 6/12/2017 Pete A Meyers, CFO, bought 350 with an average share price of $71.49 per share and the total transaction amounting to $25,021.50.
- On 5/19/2017 David Pernock, Insider, bought 255 with an average share price of $79.69 per share and the total transaction amounting to $20,320.95.
- On 5/16/2017 David Pernock, Insider, bought 200 with an average share price of $82.24 per share and the total transaction amounting to $16,448.00.
- On 4/25/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 54,180 with an average share price of $88.38 per share and the total transaction amounting to $4,788,428.40.
- On 4/3/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 91,332 with an average share price of $83.09 per share and the total transaction amounting to $7,588,775.88.
- On 3/29/2017 Proquest Investments Iv, L.P., Major Shareholder, sold 106,468 with an average share price of $83.01 per share and the total transaction amounting to $8,837,908.68.
Recent Trading for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares of Eagle Pharmaceuticals, Inc. closed the previous trading session at 47.07 up +0.30 0.64% with 547,959 shares trading hands.